Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases

Summary Psoriasis is a chronic inflammatory skin condition, characterized by T‐helper (Th) 1 and Th17 cell activation. Ustekinumab is a fully human immunoglobulin G1κ monoclonal antibody that targets the common p40 subunit that is shared by both interleukin (IL)‐12 and IL‐23, consequently inhibiting...

Full description

Saved in:
Bibliographic Details
Published in:British journal of dermatology (1951) 2013-01, Vol.168 (1), p.210-212
Main Authors: de Souza, A., Ali‐Shaw, T., Reddy, S.M., Fiorentino, D., Strober, B.E.
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal, Humanized - adverse effects
Arthritis
Arthritis, Psoriatic - chemically induced
Biological and medical sciences
Dermatologic Agents - adverse effects
Dermatology
Diseases of the osteoarticular system
Humans
Inflammatory joint diseases
Male
Medical sciences
Psoriasis - drug therapy
Psoriasis. Parapsoriasis. Lichen
Ustekinumab
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Psoriasis is a chronic inflammatory skin condition, characterized by T‐helper (Th) 1 and Th17 cell activation. Ustekinumab is a fully human immunoglobulin G1κ monoclonal antibody that targets the common p40 subunit that is shared by both interleukin (IL)‐12 and IL‐23, consequently inhibiting T‐cell differentiation along both Th1 and Th17 pathways. This is a report of two patients who developed psoriatic arthritis during ustekinumab treatment for psoriasis. Neither patient had a personal or family history of arthritis.
ISSN:0007-0963
1365-2133
DOI:10.1111/j.1365-2133.2012.11206.x